New York, March 06, 2024 - PRISM MediaWire - IceCure Medical Ltd. (Nasdaq: ICCM) has disclosed novel findings from an initial, autonomous breast cancer investigation, revealing a median tumor reduction of 100% at both six and twelve months subsequent to cryoablation in women classified as inoperable for breast cancer. IceCure's ProSense® System represents a minimally invasive cryoablation technology, which eradicates tumors through freezing, offering an alternative to conventional surgical tumor excision.
"We are exceedingly gratified by the positive outcomes observed among women categorized as inoperable in this study following cryoablation. Our efforts remain steadfast in securing approval, accessibility, and affordability of ProSense® for a broad demographic of women across various nations globally."
Eyal Shamir, CEO of IceCure
Highlights
- IceCure conducted a single-site clinical trial involving ultrasound-guided cryoablation utilizing ProSense® on 39 women aged 60-92. These participants had biopsy-confirmed malignant lesions and were classified as inoperable due to advanced age and comorbidities, or personal refusal of surgery.
- Monitoring of patients occurred at intervals of 1, 3, 6, and 12 months post-procedure, during which tumor size reduction rates were assessed via ultrasound. At the 12-month mark post-procedure, the efficacy of the intervention was further examined through core needle biopsy of the post-procedural scar and contrast-enhanced mammography (CEM) to ascertain the presence or absence of residual tumoral cells and evaluate the effectiveness of cryoablation.
- Notably, ProSense® holds approval in Italy for various indications, including breast cancer. The ProSense® System provides a minimally invasive procedure requiring approximately 40 minutes for completion.
About IceCure Medical
IceCure Medical (Nasdaq: ICCM) develops and markets ProSense®, an advanced liquid-nitrogen-based cryoablation therapy for the treatment of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective alternative to hospital surgical tumor removal that is easily performed in a relatively short procedure. The system is marketed and sold worldwide for the indications cleared and approved to date including in the U.S., Europe and China.
About PRISM MediaWire:
PRISM MediaWire provides access to leading financial and trade media outlets, along with key trading platforms. This positions companies at the center of financial market dialogues and trends, providing significant visibility in the competitive capital markets. PRISM MediaWire’s distribution service is further augmented by:
- 24/7 Support: Clients benefit from round-the-clock access to PRISM MediaWire's dedicated support team, ensuring timely assistance is always available.
- Competitive Pricing: PRISM MediaWire offers its top-tier newswire distribution services at competitive rates, providing value for its clients.
- Unlimited Word Count: There are no restrictions on the length of press releases, allowing clients the flexibility to convey their messages comprehensively without word count limitations.
- No Extra Fee for Embedded Images and Videos: PRISM MediaWire enables clients to augment their press releases with images and videos, enhancing their content's visual appeal and engagement, without incurring additional costs.
Learn more about the PRISM Advantage: https://www.youtube.com/watch?v=yk5_Jq8jJPE
Visit our website, prismmediawire.com, and follow us on X.
PRISM MediaWire - Social Media (X)
Contact:
PRISM MediaWire - News & Blog